The goal of this clinical trial is to find out if an artificial intelligence (AI)-enhanced mobile app can help people with coronary heart disease (CHD) better manage their health after being discharged from the hospital. The main questions it aims to answer are: 1. Does the AI-enhanced app help lower bad cholesterol (LDL-C) levels within 3 months after leaving the hospital? 2. Does the app improve other health measures, like blood pressure, blood sugar control, weight, medication adherence and cardiac events? Researchers will compare the AI-enhanced app to usual care, where participants receive usual health advice without using the app. Participants will: 1. Be randomly assigned to use either the AI-enhanced app or receive usual care. 2. Use the app to track and manage their health, receive reminders, and get educational tips. 3. Attend checkups at 3 months to measure cholesterol levels and other health outcomes. The study hopes to show that using an AI-enhanced app can make it easier for people with CHD to stay healthy and avoid future heart problems.
The AIM-CHD app was developed by a diverse team at Fuwai Hospital, including doctors, nurses, patients, and software engineers. It gathers information from synchronized hospital records, questionnaires, intelligent voice follow-ups, and wearable devices. Using this data, it categorizes patients by risk level, detects unmanaged risk factors, and generates individualized follow-up schedules and intervention plans. When risk factors are not well controlled, the app alerts patients to these issues. It also reminds users to monitor their health markers regularly, follow prescribed medication routines, and offers personalized health education focused on lifestyle adjustments. The app can assess the severity of blood pressure, heart rate, blood glucose, and lipid levels, advising patients to seek in-person consultations if necessary. AIM-CHD also recognizes emergency scenarios and provides options for online consultations or immediate help from Fuwai Hospital to prevent treatment delays. The platform leverages artificial intelligence (AI) for efficient lab report image recognition and speech-to-text conversion, streamlining follow-up care. Additionally, it offers customized patient education. The AIM-CHD's intervention goals and strategies are grounded in the latest clinical guidelines. The system is built with a front-end and back-end separation architecture: the back-end is developed with the .NET framework using C#, while the front-end is a WeChat mini-program created with JavaScript and React.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
1,100
The AIM-CHD platform synchronizes data from hospitalization records, questionnaires, AI-powered voice follow-ups, and wearable devices to perform risk stratification and manage uncontrolled risk factors. It provides individualized follow-up plans, medication reminders, and lifestyle education, with real-time assessments of vital health metrics to prompt necessary in-person consultations. The app offers online consultation access and emergency services through Fuwai Hospital. Additionally, it delivers personalized patient education, aligning with the latest clinical guidelines.
Usual post-discharge care includes oral and written instructions on sustained pharmacotherapy regimens, recommended follow-up frequency, and lifestyle modifications.
Fuwai Hospital, Chinese Academy of Medical Sciences/National Center for Cardiovascular Diseases
Beijing, Beijing Municipality, China
LDL-C levels
LDL-C levels (mmol/L)
Time frame: measured at 3 months post-discharge.
LDL-C Target Attainment Rate
Proportion of patients achieving LDL-C \<1.8 mmol/L
Time frame: assessed at 3 months post-discharge
Blood Pressure Control Rate
Proportion of patients with controlled blood pressure, defined as systolic pressure \<130 mmHg and diastolic pressure \<80 mmHg.
Time frame: assessed at 3 months post-discharge
Glycosylated Hemoglobin Levels
Time frame: assessed at 3 months post-discharge
Smoking Rate
Proportion of patients who are still smoking
Time frame: assessed at 3 months post-discharge
BMI
body mass index
Time frame: assessed at 3 months post-discharge
Cardiovascular Composite Endpoint Events
Incidence of all-cause mortality, non-fatal myocardial infarction, stroke, and rehospitalization.
Time frame: assessed at 3 months post-discharge
Medication Adherence
Proportion of patients adhering to antiplatelet agents and statins, defined as taking medications for more than 80% of the prescribed time over the past month.
Time frame: assessed at 3 months post-discharge
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.